Skip to content

Evaluation of Platelet Rich Fibrin Matrix as Regenerative Material in Intraosseous Defects

Evaluation of Platelet Rich Fibrin Matrix(PRFM) as a Regenerative Material in Surgical Management of Human Periodontal Intraosseous Defects:A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03616925
Enrollment
30
Registered
2018-08-06
Start date
2013-09-30
Completion date
2014-11-30
Last updated
2018-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regenerative Inflammation

Brief summary

Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood. Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing. Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.

Detailed description

Periodontitis is a chronic inflammatory disease caused by bacterial Plaque, the onset and progression of which is modulated by a variety of risk factors such as systemic conditions and smoking. It causes pathological alterations of the periodontium, resulting in loss of connective tissue attachment to the tooth, apical migration of the junctional epithelium along the root surface and loss of supporting alveolar bone. If left untreated, cases of periodontal disease can lead to premature tooth loss. However, the complex structure of periodontium, which consist of soft connective tissue of gingiva and periodontal ligament, as well as the mineralized tissues, cementum and bone, makes periodontal wound healing a unique process. Although, all the tissues of the periodontium get affected, the crux of the problem of chronic periodontal diseases lies in the changes that occur in the bone resulting in intraosseous defects of various architecture, the persistence of which even after completion of active periodontal treatment may increase the site-specific risk of progression of periodontitis. The two primary components of periodontal therapy involves, the elimination of the periodontal infection by eliminating the pathogenic periodontal microflora which induces favourable clinical changes in the periodontium and substantial efforts should be made to alter the anatomic defect resulting from active periodontitis. The resective surgical approach and mucogingival surgeries (MGS) were the major periodontal therapies until the 1970s. However, problems with esthetics, root sensitivity and root caries resulting from resective therapy for severe periodontitis were eventually pointed out. Also resective procedure was admitted to be a Repair and not Regeneration which has long been the goal of periodontal therapy. The past two decades has seen a radical change in periodontal surgery with a shift from resective periodontal surgery to regenerative therapies. Also the concept of treatment has changed towards regeneration with a goal of regaining natural periodontal apparatus. Conventional surgical approaches (e.g., flap debridement) continue to offer time-tested and reliable methods to access root surfaces, reduce periodontal pockets and attain improved periodontal form/architecture. However, these techniques offer only limited potential to recover tissues, destroyed during earlier disease phases. Broad ranges of treatment options are available, but only some are regarded as truly regenerative procedures. Periodontal regeneration is a complex process which requires an orchestrated sequence of biologic events, such as cell migration, adherence, growth, and differentiation involving a large number of growth factors and cytokines for its regulation.To accelerate clinical translation of the same, there is an ongoing need to develop therapeutics based on endogenous regenerative technology (ERT), which can stimulate latent self-repair mechanisms in patients and harness the host's innate capacity for regeneration. ERT in periodontics applies the patient's own regenerative 'tools', that is, patient-derived growth factors (GFs) and fibrin scaffolds, to create a material niche in an injured site where the progenitor/stem cells from neighbouring tissues can be recruited for (in situ) periodontal regeneration. Growth factors are naturally occurring proteins that function in the body to promote the mitogenesis (proliferation), directed migration and metabolic activity of cells. Numerous growth factors have been identified, the expression of which following bone and soft tissue injury may regulate the repair and regenerative process. Platelets apart from their role in haemostasis have been reported to possess regenerative potential as their alpha granules are rich sources of various vital growth factors. These growth factors such as platelet derived growth factor, transforming growth factor β1, epithelial growth factor, vascular endothelial growth factor, insulin like growth factor and fibroblast growth factor whether used alone or in combination have been extensively studied and shown to promote the regeneration of oral and maxillofacial bone defects. Platelet growth factors may initiate healing by attracting undifferentiated cells within the fibrin matrix that is formed in the very early stages of healing process and by triggering cell division. Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors. Locally delivered platelet concentrates are supposed to increase the proliferation of connective tissue progenitors to stimulate fibroblast and osteoblast activity and enhance angiogenesis, all of which are fundamental to tissue healing and regeneration. Several techniques for platelet concentrates are available, each method leading to a different product with different biology and potential use. Different platelet concentrates are classified, depending on their leucocyte and fibrin content. Conventional platelet rich plasma (PRP), also known as first generation platelet concentrate is plasma with a platelet concentration above the normal physiologic levels found in blood. Currently several methods are available for PRP preparation, most producing a liquid end product to promote tissue repair. Due to poor mechanical properties, conventional PRP is often difficult to handle in clinical settings that require secure implantation in a specific site or where released growth factors could be washed out during an operation. The physical properties of PRP can be changed if plasma and platelets are stimulated by the addition of calcium chloride and thrombin. The exogenous activation of platelets using bovine thrombin at the time of PRP preparation result in an almost immediate degranulation and disintegration of platelet granules. Consequently, complete growth factor release will take place at the time of PRP preparation and placement. Since wound healing requires a sequential appearance of vessels and cells over time, the immediate and almost complete release of platelet granules may have very little beneficial effect on later stages of healing. In contrast, Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application. PRFM possesses the ability to enhance tissue repair by isolation, concentration and preservation of autologous platelets in a dense scaffold like fibrin matrix. The viable platelets contain intrinsic growth factors which are probably released in a desired spatial and temporal manner that affect every aspect of soft tissue and osseous healing. Very limited studies have been conducted to assess the regenerative potential of this new modality i.e. PRFM. This study therefore aims at the evaluation of platelet rich fibrin matrix as a potential regenerative material in comparison with open flap debridement in human periodontal intraosseous defects.

Interventions

BIOLOGICALPlatelet Rich Fibrin Matrix kit

Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine

PROCEDUREsurgical open flap debridement

only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit

Sponsors

KLE Society's Institute of Dental Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The patients for this study were selected from the outpatient section of the Department of Periodontics, KLE Society's institute of Dental Sciences, Bangalore, Karnataka. Fifteen patients, aged between 30-55 years (10 males and 5 females) diagnosed with chronic periodontitis, contributing to 30 sites were enrolled for the study by convenience sampling method. It was made clear to the potential subjects that participation was voluntary. Written informed consent was obtained from patients, and ethical clearance for the study was received from the Institutional Ethics Committee (IEC), KLE Society's institute of Dental Sciences, Bangalore. This Randomized controlled trial was carried out from November 2013 to October 2014.

Eligibility

Sex/Gender
ALL
Age
30 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy patients diagnosed with chronic periodontitis. * Patients with bilateral infra bony pocket measuring ≥ 6mm with radiographic evidence of intrabony defect.

Exclusion criteria

* Pregnant /lactating women * Patients taking any drug known to affect the number and function of platelets in the past 3 months. * Patients with abnormal platelet count. * Patients with immunologic diseases * Current smokers.

Design outcomes

Primary

MeasureTime frameDescription
the clinical change in regenerative potential of platelet rich fibrin matrix (PRFM) and open flap debridement (OFD) and OFD alone in periodontal defects.baseline,3 months and 6 monthsClinical parameters(plaque index, gingival index, probing pocket depth,attachment level)were combined to assess the change in the regenerative potential
Early wound healing index (EHI) was used to assess the wound healing potential of PRFM1 weekEarly wound healing index (EHI) was used to assess the wound healing potential of PRFM at 1 week.
change in the radiographic parameters in both the groups i.e,PRFM+OFD and OFD alonebaseline,3 months,6 monthsradiographic evidence of bilateral vertical osseous defects were categorized into test group \[OFD + PRFM and control group \[open flap debridement (OFD)\]

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026